A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 1, 2015, Pages 79-88

  Iqbal, Muzaffar ^a   Khalil, Nasr Y ^a   Imam, Faisal ^a   Khalid Anwer, Md ^b  

^a KING SAUD UNIVERSITY   (Saudi Arabia)

^b PRINCE SATTAM BIN ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

High throughput; Pharmacokinetics; Rivaroxaban; UHPLC MS MS

Indexed keywords

BLOOD CLOTTING FACTOR 10A INHIBITOR; MORPHOLINE DERIVATIVE; RIVAROXABAN; THIOPHENE DERIVATIVE;

HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MASS SPECTROMETRY; PLASMA; PROCEDURES;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FACTOR XA INHIBITORS; HUMANS; MASS SPECTROMETRY; MORPHOLINES; PLASMA; THIOPHENES;

EID: 84939894733     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1121-2     Document Type: Article

References (25)

1. Mann KG, Brummel K, Butenas S (2003) What is all that thrombin for? J Thromb Haemost 1:1504–1514
2. Turpie AG (2007) Oral, direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases. Arterioscler Thromb Vasc Biol 27:1238–1247
3. Kreutz R (2012) Pharmacodynamic and pharmacokinetic basics of rivaroxaban. Fund Clin Pharmacol 26:27–32
4. Lindhoff-Last E, Samama MM, Ortel TL, Weitz JI, Spiro TE (2010) Assays for measuring rivaroxaban: their suitability and limitations. Ther Drug Monit 32:673–679
5. Sarich TC, Peters G, Berkowitz SD, Misselwitz F, Nessel CC, Burton P et al (2013) Rivaroxaban: a novel oral anticoagulant for the prevention and treatment of several thrombosis-mediated conditions. Ann N Y Acad Sci 1291:42–55
6. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G (2005) Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther 78:412–421
7. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M (2005) Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939–an oral, direct Factor Xa inhibitor–after multiple dosing in healthy male subjects. Eur J Clin Pharmacol 61:873–880
8. Mueck W, Stampfuss J, Kubitza D, Becka M (2014) Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban. Clin Pharmacokinet 53:1–16
9. Kreutz R (2014) Pharmacokinetics and pharmacodynamics of rivaroxaban–an oral, direct factor Xa inhibitor. Curr Clin Pharmacol 9:75–83
10. Mueck W, Schwers S, Stampfuss J (2013) Rivaroxaban and other novel oral anticoagulants: pharmacokinetics in healthy subjects, specific patient populations and relevance of coagulation monitoring. Thromb J 11:10
11. Risselada AJ, Visser MJ, van Roon E (2013) Pulmonary embolism due to interaction between rivaroxaban and carbamazepine. Ned tijdschrift voor geneeskunde 157:A6568
12. Douxfils J, Tamigniau A, Chatelain B, Chatelain C, Wallemacq P, Dogne JM et al (2013) Comparison of calibrated chromogenic anti-Xa assay and PT tests with LC-MS/MS for the therapeutic monitoring of patients treated with rivaroxaban. Thromb Haemost 110:723–731
13. Harenberg J, Erdle S, Marx S, Kramer R (2012) Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost 38:178–184
14. Rohde G (2008) Determination of rivaroxaban–a novel, oral, direct Factor Xa inhibitor–in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatog B 872:43–50
15. Gous T, Couchman L, Patel JP, Paradzai C, Arya R, Flanagan RJ (2014) Measurement of the Direct Oral Anticoagulants Apixaban, Dabigatran, Edoxaban, and Rivaroxaban in Human Plasma Using Turbulent Flow Liquid Chromatography With High-Resolution Mass Spectrometry. Ther Drug Monit. doi:10.1097/FTD.0000000000000059.
16. Magiera S (2013) Fast, simultaneous quantification of three novel cardiac drugs in human urine by MEPS-UHPLC-MS/MS for therapeutic drug monitoring. J Chromatog B 938:86–95
17. US Food and Drug Administration (2001) Guidance for Industry on Bioanalytical Method Validation. Center for Drug Evaluation and Research (CDER). US Food and Drug Administration, Rockville
18. European Medicines Agency (2011) Guideline on bioanalytical method validation. CHMP. European Medicines Agency, London
19. Samama MM, Contant G, Spiro TE, Perzborn E, Flem LL, Guinet C et al (2012) Evaluation of the prothrombin time for measuring rivaroxaban plasma concentrations using calibrators and controls: results of a multicenter field trial. Clin Appl Thromb Hemost 18:150–158
20. Samama MM, Contant G, Spiro TE, Perzborn E, Guinet C, Gourmelin Y et al (2012) Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost 107:379–387
21. Mani H, Rohde G, Stratmann G, Hesse C, Herth N, Schwers S et al (2012) Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost 108:191–198
22. Lippi G, Ardissino D, Quintavalla R, Cervellin G (2014) Urgent monitoring of direct oral anticoagulants in patients with atrial fibrillation: a tentative approach based on routine laboratory tests. J Thromb Thrombolyis 38(2):269–274
23. Liu G, Snapp HM, Ji QC, Arnold ME (2009) Strategy of accelerated method development for high-throughput bioanalytical assays using ultra high-performance liquid chromatography coupled with mass spectrometry. Anal Chem 81:9225–9232
24. Kumar A, Saini G, Nair A, Sharma R (2012) UPLC: a preeminent technique in pharmaceutical analysis. Acta Poly Pharm 69:371–380
25. Zheng N, Zeng J, Akinsanya B, Buzescu A, Xia YQ, Ly V et al (2013) A rapid, accurate and robust UHPLC-MS/MS method for quantitative determination of BMS-927711, a CGRP receptor antagonist, in plasma in support of non-clinical toxicokinetic studies. J Pharm Biomed Anal 283:237–248